SB 690, the Overdose RADAR Act, is a federal public health and drug policy bill aimed at improving the response to the fentanyl and broader opioid overdose crisis. It would authorize new grant programs and expand existing ones to improve overdose surveillance, data collection, and reporting, including better postmortem toxicology testing, electronic death reporting, data linkage across systems, and more complete tracking of fatal and nonfatal overdoses. The bill also directs federal agencies to coordinate more closely on drug data standards and reporting, and it includes a policy statement that the Director of the Office of National Drug Control Policy should be Cabinet-level.
The bill would also expand prevention and response tools. It creates a CDC pilot program for wastewater testing to detect illicit substances such as fentanyl and xylazine, broadens opioid overdose grant uses to include administering overdose-reversal drugs, and adds a new grant program for elementary and secondary schools to stock and administer emergency overdose treatment medications and devices. In addition, it amends federal law to treat fentanyl test strips as drug paraphernalia exceptions, which would make them easier to distribute and use for harm-reduction purposes.
If enacted, SB 690 would amend multiple federal statutes, including the Public Health Service Act, the Office of National Drug Control Policy Reauthorization Act, and the Controlled Substances Act. It would create new federal grant authorities for states, localities, schools, and wastewater facilities, while also changing how overdose data are collected, standardized, and reported across agencies. The bill would affect public health agencies, law enforcement data systems, schools, state attorneys general, and recipients of opioid response grants by imposing new reporting, certification, and coordination requirements.
The bill’s overall tone is strongly supportive of aggressive action against fentanyl and opioid overdoses, with an emphasis on data-driven public health interventions, harm reduction, and interagency coordination. Because there were no committee transcripts or recorded votes provided, there is no direct evidence of debate or opposition in the available record. The bill’s introduction and referral suggest it is in an early stage of consideration, with the stated purpose of combating the fentanyl crisis likely to attract support from proponents of overdose prevention and treatment expansion.
The most likely points of contention are the bill’s harm-reduction provisions and its federal role in shaping overdose policy. The fentanyl test strip provision may draw scrutiny from opponents who object to drug-checking tools or broader paraphernalia exceptions. The school-based overdose treatment grant program could also raise concerns about liability, implementation, and whether schools should be responsible for administering emergency overdose medications. More generally, the bill’s directives on overdose death classification, national data standards, and ONDCP coordination may prompt debate over federal versus state control, reporting burdens, and the scope of public health versus law enforcement approaches.